Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Lonza to set up Global Capability Centre in Hyderabad

Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies